Suche

Programmdetails

Postervorträge

TAVI bei AK-Stenose: Biomarker

Freitag, 25. April | 09:45 - 10:45 Uhr | Posterbereich 13

Vorsitz/Chair: Harald Lapp (Bad Berka), Victor Mauri (Köln)

Agenda

(P954)
Patientencharakteristika und Outcomes in TAVI-Patienten mit hohem (>50mg/dl) vs. niedrigem Lipoprotein(a), eine Analyse aus dem Breisgau-TAVI-Register
T. Maulhardt (Freiburg im Breisgau)
(P955)
Regulatory long non-coding RNAs and their potential roles in aortic diseases
A. M. Utami (Bonn)
(P956)
Elucidation of Long non-coding RNA in epigenetic regulation in aortic disease and their potential therapeutic role
J. I. Muñoz-Manco (Bonn)
(P957)
sST2 and mosaic loss of Y-chromosome: a combined biological-genomic prognostic marker related to fibrosis in aortic valve stenosis
S. Mas-Peiro (Frankfurt am Main)
(P959)
Mutational landscape and impact of clonal hematopoiesis of indeterminate potential in severe aortic valve stenosis
R. N. Jamin (Bonn)
(P960)
Valvular Cyclophilin A expression indicates calcifying phenotypes of aortic stenosis
M. Sigle (Tübingen)
Diese Seite teilen